- Home
- CTMX vs HOWL Comparison
CTMX vs HOWL Comparison
Compare CTMX & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- HOWL
- Stock Information
- Founded
- CTMX 2008
- HOWL 2017
- Country
- CTMX United States
- HOWL United States
- Employees
- CTMX N/A
- HOWL N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- CTMX Health Care
- HOWL Health Care
- Exchange
- CTMX Nasdaq
- HOWL Nasdaq
- Market Cap
- CTMX 85.3M
- HOWL 87.4M
- IPO Year
- CTMX 2015
- HOWL 2021
- Fundamental
- Price
- CTMX $0.79
- HOWL $1.28
- Analyst Decision
- CTMX Buy
- HOWL Strong Buy
- Analyst Count
- CTMX 6
- HOWL 2
- Target Price
- CTMX $5.77
- HOWL $9.50
- AVG Volume (30 Days)
- CTMX 814.8K
- HOWL 232.6K
- Earning Date
- CTMX 03-10-2025
- HOWL 03-06-2025
- Dividend Yield
- CTMX N/A
- HOWL N/A
- EPS Growth
- CTMX N/A
- HOWL N/A
- EPS
- CTMX 0.16
- HOWL N/A
- Revenue
- CTMX $126,617,000.00
- HOWL $3,386,000.00
- Revenue This Year
- CTMX $22.55
- HOWL N/A
- Revenue Next Year
- CTMX N/A
- HOWL $34.17
- P/E Ratio
- CTMX $4.85
- HOWL N/A
- Revenue Growth
- CTMX 33.66
- HOWL N/A
- 52 Week Low
- CTMX $0.78
- HOWL $1.26
- 52 Week High
- CTMX $5.85
- HOWL $8.19
- Technical
- Relative Strength Index (RSI)
- CTMX 39.47
- HOWL 41.40
- Support Level
- CTMX $0.82
- HOWL $1.26
- Resistance Level
- CTMX $0.98
- HOWL $1.45
- Average True Range (ATR)
- CTMX 0.07
- HOWL 0.09
- MACD
- CTMX 0.00
- HOWL 0.02
- Stochastic Oscillator
- CTMX 6.67
- HOWL 45.45
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.